http://www.cnr.it/ontology/cnr/individuo/prodotto/ID132261

Classification of cancer stage using the immune system. (Contributo in volume (capitolo o saggio))

Type

Prodotto della ricerca (Classe)
Contributo in volume (capitolo o saggio) (Classe)

Label

Classification of cancer stage using the immune system. (Contributo in volume (capitolo o saggio)) (literal)

Anno

2010-01-01T00:00:00+01:00 (literal)

Alternative label

Pellegrini P; Contasta I; Berghella AM; Del Beato T; and Adorno D. (2010)
Classification of cancer stage using the immune system.
Springer-Verlag, Berlin Heidelberg (Germania) in Methods of Cancer Diagnosis, Therapy and Prognosis. General Overviews, Head and Neck Cancer and Thyroid Cancer, 2010
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Pellegrini P; Contasta I; Berghella AM; Del Beato T; and Adorno D. (literal)

Pagina inizio

195 (literal)

Pagina fine

213 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni

Questo capitolo nel volume non contiene un abstract, perchè non previsto, ma il suo abstrat originale è il seguente: ABSTRACT: It is a recognised fact that an early diagnosis of disease stage in cancer can improve patient treatment and prognosis. Surgery and therapy are strictly related to cancer stage and the need for accurate staging, prior to any treatment planning has become increasingly important in a wide variety of malignancies. However, difficulties have arisen in identifying non-invasive tools for establishing reliable stage diagnosis, consequently the optimization of screening tests that can contribute to the classification of disease stage are a step forward in the treatment of cancer, especially non-invasive ones. Our experience in the field of immunology, and, in particular, our study of the physiological network of the immune system, leads us to believe that an immunological method looking at peripheral blood biomarkers could be used to establish cancer disease stage at an earlier phase. In order to establish the validity of this hypothesis, we studied the immune system network and in particular, peripheral blood TH1/TH2/TH3/TH17 type cytokines and other specific immunological and clinical parameters; samples of serum from groups of healthy subjects and patients, culture supernatants from peripheral blood dendritic cells (DC), mononuclear cells (PBMC), molecule markers and proliferative response were studied in correlation to the progression of cancer stage. Our results are proof that the evaluation of a patient's immune system is a useful, non-invasive tool for the classification of disease stage The evaluation of cytokine networks is a valid and practical tool and we believe that our research data can be considered a scientific rationale for extending this study to cover other cancer types and for a follow up involving a controlled clinical study. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#titoloVolume

Methods of Cancer Diagnosis, Therapy and Prognosis. General Overviews, Head and Neck Cancer and Thyroid Cancer (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#volumeInCollana

vol. 7 (literal)

Note

Google Scholar (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

Institute for Organ Transplantation and Immunocytology (ITOI) - CNR, L'Aquila, Italy. (literal)

Titolo

Classification of cancer stage using the immune system. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#inCollana

Methods of Cancer Diagnosis, Therapy, and Prognosis (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#isbn

978-90-481-3185-3 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autoriVolume

M.A. Hayat (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#curatoriVolume

M.A. Hayat (literal)

Abstract

In cancer research, as Jarnicki et al. (2006) and Benzoni et al. (2007) have shown, surgery continues to be the main treatment option though irradiation and chemotherapy have become increasingly important and may, in certain cases, improve the cure rate produced by surgery. The need for accurate staging, however, prior to any treatment planning has become increasingly important in a wide variety of malignancies (Vlastos and Verkooijen 2007; Warburton et al. 2007). The detection of widespread metastatic disease in patients and the need for accurate staging before therapy has been long recognized (Skeel 1992), and there is a strong case for restaging cancer after a number of cycles of chemotherapy to determine if continued chemotherapy is required. Staging during an operative procedure is also vitally important to spare the patient the possible morbidity and mortality associated with hazardous procedures. No single staging system is universally employed for all cancers but one of the most commonly used is the pTNM classification system, devised by the American Joint Committee on Cancer et al. (1992), and based on the examination of a surgically resected specimen. This classification takes into consideration the size of the primary tumour (T), the presence and extent of regional node metastases (N), and the presence of distant metastases (M). However it is an invasive method of classification as it is based on the examination of a surgically resected specimen. Many researchers have found that tumor establishment and progression are generally allowed through a malfunction of the immune response (Jarnicki et al. 2006; Berghella et al. 2006; Contasta et al. 2006; Pellegrini et al. 2006). Hence, it is our opinion that a noninvasive method of identifying disease stage could lie with the study of immunological blood parameters. (literal)

Editore